Cytorex Biosciences is a Florida-based Biopharma company with a patented technology (US Patent 7,1412,51) to treat cancer using an approach that has never been taken before: Inorganic Acids as actives.

Its lead compound is called Cytoreg.

CytoregÂ® is a combination of 4 inorganic acids and 2 organic acids in water, where The Fluoride (F- ion) of Hydrofluoric acid is the active agent.

CytoregÂ® will target and kill cancer cells without affecting normal cells, hence becoming a very effective and safe product to administer to human cancer patients.

The first indication for CytoregÂ® is Glioblastoma Multiforme, a malingnant brain tumor with a very low cure rate. CytoregÂ® can cross the blood brain barrier due to its very low molecular weight.

Clinical Trials ara expected to start late 2010 or early 2011 subject to funding.

Milestones
edit

Cytorex Biosciences added Carlos M. Garcia as Managing Director & COO.

Posted 8/9/09 at 12:31pm
Cytorex Biosciences added Edgar de Sola as Director & CMO.

Posted 8/6/09 at 8:43am
Cytorex Biosciences added William Jimenez as Director & CFO.

Posted 8/6/09 at 8:43am
Cytorex Biosciences added David Martucci as Chairman & CEO.

Posted 8/6/09 at 8:43am